{"id":"placebo-to-omalizumab","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reaction"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Muscle pain"}]},"_chembl":{"chemblId":"CHEMBL1201589","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This binding prevents the interaction of IgE with its high-affinity receptor on mast cells and basophils, thereby inhibiting the release of mediators involved in allergic inflammation. Omalizumab also reduces the levels of free IgE in the blood, which can contribute to the development of allergic symptoms.","oneSentence":"Omalizumab is a recombinant DNA-derived humanized IgG1 monoclonal antibody that selectively binds to human immunoglobulin E (IgE) with high affinity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:49.284Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic idiopathic urticaria"},{"name":"Asthma"}]},"trialDetails":[{"nctId":"NCT06042478","phase":"PHASE3","title":"Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-11-15","conditions":"Chronic Spontaneous Urticaria","enrollment":470},{"nctId":"NCT07356713","phase":"PHASE1","title":"A Study to Find a Suitable Dose of Exl-111 for Further Research","status":"RECRUITING","sponsor":"Excellergy Inc.","startDate":"2026-01-08","conditions":"Allergic Disease","enrollment":70},{"nctId":"NCT07059091","phase":"PHASE2","title":"Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-02-12","conditions":"Chronic Obstructive Pulmonary Disease (COPD), Allergies","enrollment":334},{"nctId":"NCT07342803","phase":"PHASE2","title":"Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients","status":"RECRUITING","sponsor":"Longbio Pharma","startDate":"2025-01-25","conditions":"Allergic Asthma","enrollment":200},{"nctId":"NCT03369704","phase":"PHASE3","title":"Study of Efficacy and Safety of Omalizumab in Severe Japanese Cedar Pollinosis Adult and Adolescent Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-12-15","conditions":"Seasonal Allergic Rhinitis","enrollment":337},{"nctId":"NCT06228560","phase":"PHASE2","title":"Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment","status":"COMPLETED","sponsor":"Longbio Pharma","startDate":"2024-01-26","conditions":"Chronic Spontaneous Urticaria","enrollment":202},{"nctId":"NCT02570984","phase":"PHASE2","title":"Preventing Asthma in High Risk Kids","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2018-11-27","conditions":"Asthma","enrollment":200},{"nctId":"NCT04998604","phase":"PHASE4","title":"EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-09-27","conditions":"Chronic Rhinosinusitis With Nasal Polyps, Asthma","enrollment":360},{"nctId":"NCT06824649","phase":"PHASE4","title":"Biologics in Chronic Rhinosinusitis With Nasal Polyposis","status":"NOT_YET_RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2026-03","conditions":"Chronic Sinusitis, Nasal Polyps","enrollment":504},{"nctId":"NCT04976192","phase":"PHASE3","title":"Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2021-08-30","conditions":"Chronic Urticaria","enrollment":608},{"nctId":"NCT03881696","phase":"PHASE3","title":"Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-07-22","conditions":"Peanut Allergy, Multi-food Allergy","enrollment":471},{"nctId":"NCT04180488","phase":"PHASE3","title":"Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-12-11","conditions":"Chronic Spontaneous Urticaria","enrollment":397},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT05332067","phase":"PHASE2","title":"Omalizumab Before Onset of Exacerbations","status":"RECRUITING","sponsor":"Children's National Research Institute","startDate":"2022-05-01","conditions":"Asthma in Children, Atopy, Viral Upper Respiratory Infection","enrollment":300},{"nctId":"NCT03679676","phase":"PHASE2","title":"Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2020-02-05","conditions":"Hypersensitivity, Food Allergy, Hypersensitivity, Food","enrollment":108},{"nctId":"NCT04833855","phase":"PHASE2","title":"Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria","status":"COMPLETED","sponsor":"Amgen","startDate":"2021-04-15","conditions":"Chronic Spontaneous Urticaria","enrollment":183},{"nctId":"NCT05774639","phase":"PHASE3","title":"Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria","status":"COMPLETED","sponsor":"Kashiv BioSciences, LLC","startDate":"2023-08-15","conditions":"Chronic Idiopathic Urticaria","enrollment":600},{"nctId":"NCT05564221","phase":"PHASE1","title":"A Multiple Ascending Dose, Phase 1b Study of YH35324 in Atopic Healthy Subjects or Subjects With Allergic Diseases","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2022-11-01","conditions":"Atopic Healthy Subjects, Adult Subjects With Allergic Diseases","enrollment":46},{"nctId":"NCT03580356","phase":"PHASE3","title":"A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-10-20","conditions":"Chronic Spontaneous Urticaria","enrollment":1078},{"nctId":"NCT05061524","phase":"PHASE1","title":"A FIH Study of YH35324 in Atopic Healthy Subjects or Subjects with Mild Allergic Diseases","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2021-09-26","conditions":"Atopic Healthy Subjects, Adult Subjects with Mild Allergic Diseases","enrollment":68},{"nctId":"NCT06509334","phase":"PHASE2","title":"Trial of JYB1904 in Chronic Spontaneous Urticaria.","status":"RECRUITING","sponsor":"Jemincare","startDate":"2024-08-04","conditions":"Chronic Spontaneous Urticaria","enrollment":135},{"nctId":"NCT04045301","phase":"PHASE2","title":"Omalizumab to Accelerate a Symptom-driven Multi-food OIT","status":"ACTIVE_NOT_RECRUITING","sponsor":"Philippe Bégin","startDate":"2019-11-11","conditions":"Food IgE-mediated Allergy, Immunotherapy, Omalizumab","enrollment":90},{"nctId":"NCT05960708","phase":"PHASE1","title":"A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic Diseases","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2023-08-23","conditions":"Allergic Disease, Chronic Spontaneous Urticaria, Chronic Inducible Urticaria","enrollment":30},{"nctId":"NCT06103656","phase":"PHASE2","title":"E-B-FAHF-2, Multi OIT and Xolair for Food Allergy","status":"COMPLETED","sponsor":"New York Medical College","startDate":"2016-08-20","conditions":"Food Allergy","enrollment":33},{"nctId":"NCT03580369","phase":"PHASE3","title":"A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-10-17","conditions":"Chronic Spontaneous Urticaria","enrollment":1072},{"nctId":"NCT05449535","phase":"PHASE1","title":"Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"Jemincare","startDate":"2022-05-07","conditions":"Healthy","enrollment":56},{"nctId":"NCT00434434","phase":"PHASE2","title":"A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-10","conditions":"Allergic Asthma","enrollment":61},{"nctId":"NCT04720612","phase":"PHASE2","title":"COVID-19 Immunologic Antiviral Therapy With Omalizumab","status":"UNKNOWN","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2021-10-15","conditions":"Covid19","enrollment":40},{"nctId":"NCT02966314","phase":"PHASE4","title":"Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2017-03-30","conditions":"Idiopathic Angioedema","enrollment":12},{"nctId":"NCT01716312","phase":"PHASE1","title":"Omalizumab for Lupus","status":"COMPLETED","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","startDate":"2014-01-08","conditions":"Systemic Lupus Erthematosus, Sjogren's Syndrome","enrollment":17},{"nctId":"NCT03478930","phase":"PHASE3","title":"An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-05-09","conditions":"Nasal Polyps, Chronic Rhinosinusitis","enrollment":249},{"nctId":"NCT02124226","phase":"PHASE3","title":"Low-dose Methotrexate for Change in Global Initiative for Asthma Step 5 Medications in Chronic Severe Asthma","status":"UNKNOWN","sponsor":"Universita degli Studi di Catania","startDate":"2021-12","conditions":"Low Dose Methotrexate in Severe Chronic Asthma","enrollment":102},{"nctId":"NCT00367016","phase":"PHASE4","title":"Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2004-02","conditions":"Asthma, Allergic Rhinitis, Atopic Dermatitis","enrollment":6},{"nctId":"NCT02477332","phase":"PHASE2","title":"Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-07-15","conditions":"Chronic Spontaneous Urticaria","enrollment":382},{"nctId":"NCT03328897","phase":"PHASE3","title":"Study of Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-04-26","conditions":"Chronic Spontaneous Urticaria","enrollment":418},{"nctId":"NCT02169115","phase":"PHASE2","title":"Urticaria Facticia Treatment With Omalizumab (UFO)","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2012-12","conditions":"Symptomatic Dermographism","enrollment":61},{"nctId":"NCT00555971","phase":"PHASE4","title":"Therapeutic Utility of Xolair in Patients Undergoing Aspirin Desensitization","status":"COMPLETED","sponsor":"David Lang","startDate":"2006-05","conditions":"Aspirin Sensitivity","enrollment":16},{"nctId":"NCT01723072","phase":"PHASE3","title":"Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-01-23","conditions":"Chronic Spontaneous Urticaria, Angioedema","enrollment":91},{"nctId":"NCT01157117","phase":"PHASE2","title":"OIT and Xolair® (Omalizumab) in Cow's Milk Allergy","status":"COMPLETED","sponsor":"Hugh A Sampson, MD","startDate":"2010-08","conditions":"Milk Allergy","enrollment":77},{"nctId":"NCT02879006","phase":"PHASE2","title":"E-B-FAHF-2, Multi OIT and Xolair (Omalizumab) for Food Allergy","status":"UNKNOWN","sponsor":"Xiu-Min Li","startDate":"2016-08","conditions":"Food Allergy","enrollment":33},{"nctId":"NCT03280550","phase":"PHASE3","title":"A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-11-15","conditions":"Nasal Polyps, Chronic Rhinosinusitis","enrollment":138},{"nctId":"NCT03280537","phase":"PHASE3","title":"A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-11-21","conditions":"Nasal Polyps, Chronic Rhinosinusitis","enrollment":127},{"nctId":"NCT00603785","phase":"PHASE4","title":"Effects of Anti-IgE Antibody Omalizumab on Patients With Chronic Sinusitis","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2008-01","conditions":"Chronic Sinusitis","enrollment":""},{"nctId":"NCT04210323","phase":"NA","title":"Shotblocker® Use in Subcutaneous Injection","status":"COMPLETED","sponsor":"Saglik Bilimleri Universitesi","startDate":"2018-06-05","conditions":"Chronic Spontaneous Urticaria","enrollment":90},{"nctId":"NCT02658877","phase":"PHASE4","title":"Sputum-derived Cellular Targets After Xolair (Omalizumab)","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2016-01","conditions":"Asthma","enrollment":3},{"nctId":"NCT02300701","phase":"PHASE4","title":"Role of Anti-IgE in Severe Childhood Eczema","status":"COMPLETED","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2014-12","conditions":"Atopic Eczema, Atopic Dermatitis, Child","enrollment":62},{"nctId":"NCT00890162","phase":"PHASE2","title":"A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-04-27","conditions":"Anaphylaxis, Hypotension, Bronchospasm","enrollment":16},{"nctId":"NCT02012387","phase":"PHASE2","title":"Efficacy Study of Omalizumab in Cholinergic Urticaria","status":"COMPLETED","sponsor":"Clinica Universidad de Navarra, Universidad de Navarra","startDate":"2014-01","conditions":"Cholinergic Urticaria","enrollment":24},{"nctId":"NCT02814630","phase":"NA","title":"Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic Urticaria","status":"COMPLETED","sponsor":"Asthma Inc Clinical Research Center","startDate":"2016-09","conditions":"Chronic Idiopathic Urticaria","enrollment":20},{"nctId":"NCT02388997","phase":"PHASE2","title":"Treatment With Omalizumab to Improve the Asthmatic Response to Rhinovirus Experimental Infection With Rhinovirus","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2013-02-01","conditions":"Asthma","enrollment":31},{"nctId":"NCT02049294","phase":"PHASE2, PHASE3","title":"Study of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic Bronchitis","status":"COMPLETED","sponsor":"McMaster University","startDate":"2014-03","conditions":"Steroid and/or Prednisone Dependent Asthma, Eosinophilic Bronchitis","enrollment":11},{"nctId":"NCT02392624","phase":"PHASE4","title":"A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2015-05-18","conditions":"Urticaria","enrollment":206},{"nctId":"NCT02643862","phase":"PHASE1, PHASE2","title":"Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients","status":"COMPLETED","sponsor":"Stanford University","startDate":"2015-03-18","conditions":"Food Allergy","enrollment":48},{"nctId":"NCT02626611","phase":"PHASE2","title":"Multi Immunotherapy to Test Tolerance and Xolair","status":"COMPLETED","sponsor":"Kari Christine Nadeau","startDate":"2015-12","conditions":"Food Allergy","enrollment":70},{"nctId":"NCT01713725","phase":"PHASE2","title":"Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria","status":"COMPLETED","sponsor":"Clinica Universidad de Navarra, Universidad de Navarra","startDate":"2012-03","conditions":"Chronic Urticaria","enrollment":20},{"nctId":"NCT01716754","phase":"PHASE2","title":"Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12","conditions":"Asthma","enrollment":471},{"nctId":"NCT00046748","phase":"PHASE3","title":"Efficacy and Safety of Omalizumab in Patients With Severe Persistent Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2001-12","conditions":"Asthma","enrollment":484},{"nctId":"NCT01066104","phase":"PHASE2","title":"Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal Polyposis","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2009-12","conditions":"Chronic Rhinosinusitis, Nasal Polyps","enrollment":27},{"nctId":"NCT00096954","phase":"PHASE4","title":"A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2006-02","conditions":"Asthma","enrollment":333},{"nctId":"NCT01430403","phase":"PHASE4","title":"Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-09","conditions":"Asthma","enrollment":478},{"nctId":"NCT00604786","phase":"NA","title":"The Effect of Omalizumab on Responses to Cat Allergen Challenge","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2007-07","conditions":"Allergic Rhinitis","enrollment":18},{"nctId":"NCT01580592","phase":"PHASE2","title":"Cold Urticaria Treatment With Xolair","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2012-04","conditions":"Cold Contact Urticaria","enrollment":31},{"nctId":"NCT00396409","phase":"PHASE3","title":"Efficacy/ Safety of Omalizumab in Patients With Seasonal Allergic Asthma and Seasonal Allergic Rhinoconjunctivitis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-02","conditions":"Allergic Asthma","enrollment":128},{"nctId":"NCT00851370","phase":"PHASE2","title":"Exploratory Study of Xolair in Chronic Obstructive Pulmonary Disease in Patients With Elevated IgE Levels","status":"WITHDRAWN","sponsor":"National Jewish Health","startDate":"2009-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":""},{"nctId":"NCT00377572","phase":"PHASE4","title":"Inner-City Anti-IgE Therapy for Asthma","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-10","conditions":"Asthma","enrollment":419},{"nctId":"NCT03019237","phase":"NA","title":"Effect of Intranasal Anti-IgE Antibodies on IgE Production","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2012-11","conditions":"Allergy","enrollment":15},{"nctId":"NCT00078195","phase":"PHASE2","title":"Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-04","conditions":"Hay Fever, Hypersensitivity, Allergy","enrollment":168},{"nctId":"NCT02329223","phase":"PHASE3","title":"Study of Efficacy and Safety of Omalizumab in Refractory Chronic Spontaneous Urticaria Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-12","conditions":"Chronic Spontaneous Uriticaria","enrollment":218},{"nctId":"NCT00267202","phase":"PHASE4","title":"Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-12","conditions":"Allergic Asthma","enrollment":275},{"nctId":"NCT01703312","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy of QGE031 Compared to Omalizumab in Patients With Allergic Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-11","conditions":"Allergic Asthma","enrollment":37},{"nctId":"NCT01976208","phase":"PHASE2, PHASE3","title":"Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma","status":"COMPLETED","sponsor":"Shanghai Zhangjiang Biotechnology Limited Company","startDate":"2010-12","conditions":"Allergic Asthma","enrollment":630},{"nctId":"NCT01599637","phase":"PHASE2","title":"Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-04","conditions":"Chronic Idiopathic Urticaria","enrollment":40},{"nctId":"NCT01202903","phase":"PHASE3","title":"Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-09","conditions":"Persistent Allergic Asthma","enrollment":616},{"nctId":"NCT01544348","phase":"PHASE1","title":"A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2012-01","conditions":"Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis","enrollment":295},{"nctId":"NCT01125748","phase":"PHASE4","title":"A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2010-05","conditions":"Allergic Asthma","enrollment":176},{"nctId":"NCT01003301","phase":"PHASE2","title":"The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2009-10","conditions":"Cat Allergy","enrollment":19},{"nctId":"NCT00139152","phase":"PHASE4","title":"Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair","status":"COMPLETED","sponsor":"Creighton University","startDate":"2005-09","conditions":"Lung Disease","enrollment":65},{"nctId":"NCT01287117","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2011-02","conditions":"Chronic Idiopathic Urticaria","enrollment":319},{"nctId":"NCT01264939","phase":"PHASE3","title":"A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2011-02","conditions":"Chronic Idiopathic Urticaria","enrollment":336},{"nctId":"NCT01292473","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2011-03","conditions":"Chronic Idiopathic Urticaria","enrollment":323},{"nctId":"NCT00670930","phase":"PHASE4","title":"Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-04","conditions":"Allergic Asthma","enrollment":36},{"nctId":"NCT01007149","phase":"PHASE3","title":"Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-09","conditions":"Asthma","enrollment":79},{"nctId":"NCT00673218","phase":"PHASE4","title":"The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils","status":"UNKNOWN","sponsor":"Creighton University","startDate":"2007-06","conditions":"Allergy","enrollment":25},{"nctId":"NCT00079937","phase":"PHASE3","title":"Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-04","conditions":"Asthma","enrollment":628},{"nctId":"NCT00314574","phase":"PHASE3","title":"A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2005-12","conditions":"Asthma","enrollment":850},{"nctId":"NCT00870584","phase":"PHASE4","title":"Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-03","conditions":"Persistent Allergic Asthma","enrollment":271},{"nctId":"NCT00481676","phase":"PHASE2","title":"Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-05","conditions":"Chronic Urticaria","enrollment":49},{"nctId":"NCT00787917","phase":"PHASE4","title":"An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-11","conditions":"Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis","enrollment":14},{"nctId":"NCT00454051","phase":"PHASE4","title":"Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-12","conditions":"Asthma","enrollment":31},{"nctId":"NCT01393340","phase":"PHASE2","title":"Clinical and Biological Effects of Anti-IgE (Omalizumab) in Patients With Bilateral Nasal Polyposis and Asthma","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2006-12","conditions":"Nasal Polyposis, Asthma","enrollment":23},{"nctId":"NCT00624832","phase":"PHASE4","title":"A Study of Efficacy of New Doses of Xolair to Protect From Allergen Challenge in Groups of Asthma Patients Defined by IgE Levels","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-02","conditions":"Asthma","enrollment":60},{"nctId":"NCT01113437","phase":"PHASE2, PHASE3","title":"Omalizumab in Non-atopic Asthma","status":"UNKNOWN","sponsor":"King's College London","startDate":"2010-04","conditions":"Bronchial Asthma","enrollment":40},{"nctId":"NCT00822783","phase":"PHASE4","title":"Study to Determine the Effect of an Anti-IgE Agent on Inflammatory Cells in the Skin of Atopic Dermatitis Patients","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2001-10","conditions":"Atopic Dermatitis","enrollment":""},{"nctId":"NCT00691873","phase":"PHASE4","title":"Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids","status":"COMPLETED","sponsor":"University of Mississippi Medical Center","startDate":"2006-05","conditions":"Asthma","enrollment":14},{"nctId":"NCT00329381","phase":"PHASE4","title":"Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy","status":"COMPLETED","sponsor":"University of Mississippi Medical Center","startDate":"2006-05","conditions":"Asthma","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to omalizumab","genericName":"Placebo to omalizumab","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Omalizumab is a recombinant DNA-derived humanized IgG1 monoclonal antibody that selectively binds to human immunoglobulin E (IgE) with high affinity. Used for Chronic idiopathic urticaria, Asthma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}